TherapeuticsMD Inc. Granted Two New Patents

BOCA RATON, Fla.--()--TherapeuticsMD Inc. (NYSE MKT:TXMD), an innovative women’s healthcare company, today announced that the U.S. Patent and Trademark Office has issued two new patents related to the company’s proprietary SYMBODA™ technology platform. The new patents are U.S. patent No. 8,846,648, related to methods of treating menopause symptoms with the company’s combination bio-identical estradiol and bio-identical progesterone technology, and U.S. patent No. 8,846,649, related to the company’s hormone formulation compositions.

“With these two new issued patents, we have strengthened the patent portfolio for our technology platform and the important new drug candidates that it enables,” said TherapeuticsMD CEO Robert G. Finizio. “These patents directly support our late-stage pipeline of investigational bio-identical hormone therapy products and could help enable a new wave of earlier-stage product candidates to meet women’s needs.”

About TherapeuticsMD Inc.

TherapeuticsMD Inc. is an innovative healthcare company focused on developing and commercializing products exclusively for women. TherapeuticsMD is developing advanced hormone therapy pharmaceutical products based on novel technologies that enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. The company also manufactures and distributes branded and generic prescription prenatal vitamins, as well as over-the-counter vitamins and cosmetics, under the vitaMedMD® and BocaGreenMD® brands. More information is available at the following websites: www.therapeuticsmd.com, www.vitamedmd.com, www.vitamedmdrx.com and www.bocagreenmd.com.

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may include, but are not limited to, statements relating to TherapeuticsMD’s objectives, plans and strategies as well as statements, other than historical facts, that address activities, events or developments that the company intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,” “plans,” “will,” “expects,” “estimates,” “projects,” “positioned,” “strategy” and similar expressions and are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and the company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of the company’s control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled “Risk Factors” in the company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, and include the following: the company’s ability to maintain or increase sales of its products; its ability to develop and commercialize its hormone therapy drug candidates and obtain additional financing necessary therefor; the length, cost and uncertain results of its clinical trials; the potential of adverse side effects or other safety risks that could preclude the approval of the company’s hormone therapy drug candidates; its reliance on third parties to conduct its clinical trials, research and development and manufacturing; the availability of reimbursement from government authorities and health insurance companies for the company’s products; the impact of product liability lawsuits; and the influence of extensive and costly government regulation.

PDF copies of the company’s historical press releases and financial tables can be viewed and downloaded at our website: www.therapeuticsmd.com/pressreleases.aspx.

Contacts

TherapeuticsMD Inc.
Dan Cartwright, 561-961-1900
Chief Financial Officer
Dan.Cartwright@TherapeuticsMD.com
or
Julia Amadio, 561-961-1900
Chief Product Officer
Julia.Amadio@TherapeuticsMD.com

Release Summary

TherapeuticsMD granted two new patents

Contacts

TherapeuticsMD Inc.
Dan Cartwright, 561-961-1900
Chief Financial Officer
Dan.Cartwright@TherapeuticsMD.com
or
Julia Amadio, 561-961-1900
Chief Product Officer
Julia.Amadio@TherapeuticsMD.com